Cargando…

The role of anxious distress in immune dysregulation in patients with major depressive disorder

Although depression with anxious distress appears to be a clinically relevant subtype of major depressive disorder (MDD), whether it involves specific pathophysiology remains unclear. Inflammation has been implicated, but not comprehensively studied. We examined within a large MDD sample whether anx...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaspersz, Roxanne, Lamers, Femke, Wittenberg, Gayle, Beekman, Aartjan T. F., van Hemert, Albert M., Schoevers, Robert A., Penninx, Brenda W. J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802575/
https://www.ncbi.nlm.nih.gov/pubmed/29217840
http://dx.doi.org/10.1038/s41398-017-0016-3
_version_ 1783298546879954944
author Gaspersz, Roxanne
Lamers, Femke
Wittenberg, Gayle
Beekman, Aartjan T. F.
van Hemert, Albert M.
Schoevers, Robert A.
Penninx, Brenda W. J. H.
author_facet Gaspersz, Roxanne
Lamers, Femke
Wittenberg, Gayle
Beekman, Aartjan T. F.
van Hemert, Albert M.
Schoevers, Robert A.
Penninx, Brenda W. J. H.
author_sort Gaspersz, Roxanne
collection PubMed
description Although depression with anxious distress appears to be a clinically relevant subtype of major depressive disorder (MDD), whether it involves specific pathophysiology remains unclear. Inflammation has been implicated, but not comprehensively studied. We examined within a large MDD sample whether anxious distress and related anxiety features are associated with differential basal inflammation and innate cytokine production capacity. Data are from 1078 MDD patients from the Netherlands Study of Depression and Anxiety. In addition to the DSM-5 anxious distress specifier, we studied various dimensional anxiety scales (e.g. Inventory of Depressive Symptomatology anxiety arousal subscale [IDS-AA], Beck Anxiety Inventory [BAI], Mood and Anxiety Symptoms Questionnaire Anxious Arousal scale [MASQ-AA]). The specifier was constructed using five self-report items from the IDS and BAI. Basal inflammatory markers included C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α. Innate production capacity was assessed by 13 lipopolysaccharide (LPS)-stimulated inflammatory markers. Basal and LPS-stimulated inflammation index scores were created. Basal inflammation was not associated with anxious distress (prevalence = 54.3%) in MDD patients, except for a modest positive association for BAI score. However, anxious distress was associated with higher LPS-stimulated levels (interferon-γ, IL-6, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, matrix metalloproteinase (MMP)-2, TNF-α, LPS-stimulated index). Other anxiety indicators (anxious distress specifier score, BAI, MASQ-AA) were also associated with increased innate production capacity. Within a large MDD sample, the anxious distress specifier was associated with increased innate cytokine production capacity but not with basal inflammation. Results from dimensional anxiety indicators largely confirm these results. These findings provide new insight into the pathophysiology of anxious depression.
format Online
Article
Text
id pubmed-5802575
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58025752018-02-08 The role of anxious distress in immune dysregulation in patients with major depressive disorder Gaspersz, Roxanne Lamers, Femke Wittenberg, Gayle Beekman, Aartjan T. F. van Hemert, Albert M. Schoevers, Robert A. Penninx, Brenda W. J. H. Transl Psychiatry Article Although depression with anxious distress appears to be a clinically relevant subtype of major depressive disorder (MDD), whether it involves specific pathophysiology remains unclear. Inflammation has been implicated, but not comprehensively studied. We examined within a large MDD sample whether anxious distress and related anxiety features are associated with differential basal inflammation and innate cytokine production capacity. Data are from 1078 MDD patients from the Netherlands Study of Depression and Anxiety. In addition to the DSM-5 anxious distress specifier, we studied various dimensional anxiety scales (e.g. Inventory of Depressive Symptomatology anxiety arousal subscale [IDS-AA], Beck Anxiety Inventory [BAI], Mood and Anxiety Symptoms Questionnaire Anxious Arousal scale [MASQ-AA]). The specifier was constructed using five self-report items from the IDS and BAI. Basal inflammatory markers included C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-α. Innate production capacity was assessed by 13 lipopolysaccharide (LPS)-stimulated inflammatory markers. Basal and LPS-stimulated inflammation index scores were created. Basal inflammation was not associated with anxious distress (prevalence = 54.3%) in MDD patients, except for a modest positive association for BAI score. However, anxious distress was associated with higher LPS-stimulated levels (interferon-γ, IL-6, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, matrix metalloproteinase (MMP)-2, TNF-α, LPS-stimulated index). Other anxiety indicators (anxious distress specifier score, BAI, MASQ-AA) were also associated with increased innate production capacity. Within a large MDD sample, the anxious distress specifier was associated with increased innate cytokine production capacity but not with basal inflammation. Results from dimensional anxiety indicators largely confirm these results. These findings provide new insight into the pathophysiology of anxious depression. Nature Publishing Group UK 2017-12-08 /pmc/articles/PMC5802575/ /pubmed/29217840 http://dx.doi.org/10.1038/s41398-017-0016-3 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Gaspersz, Roxanne
Lamers, Femke
Wittenberg, Gayle
Beekman, Aartjan T. F.
van Hemert, Albert M.
Schoevers, Robert A.
Penninx, Brenda W. J. H.
The role of anxious distress in immune dysregulation in patients with major depressive disorder
title The role of anxious distress in immune dysregulation in patients with major depressive disorder
title_full The role of anxious distress in immune dysregulation in patients with major depressive disorder
title_fullStr The role of anxious distress in immune dysregulation in patients with major depressive disorder
title_full_unstemmed The role of anxious distress in immune dysregulation in patients with major depressive disorder
title_short The role of anxious distress in immune dysregulation in patients with major depressive disorder
title_sort role of anxious distress in immune dysregulation in patients with major depressive disorder
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802575/
https://www.ncbi.nlm.nih.gov/pubmed/29217840
http://dx.doi.org/10.1038/s41398-017-0016-3
work_keys_str_mv AT gasperszroxanne theroleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT lamersfemke theroleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT wittenberggayle theroleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT beekmanaartjantf theroleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT vanhemertalbertm theroleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT schoeversroberta theroleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT penninxbrendawjh theroleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT gasperszroxanne roleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT lamersfemke roleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT wittenberggayle roleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT beekmanaartjantf roleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT vanhemertalbertm roleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT schoeversroberta roleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder
AT penninxbrendawjh roleofanxiousdistressinimmunedysregulationinpatientswithmajordepressivedisorder